Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials

BACKGROUND: The immunogenicity profile of the 9-valent HPV (9vHPV) vaccine was evaluated across five phase III clinical studies conducted in girls and boys 9–15 years of age and young women 16–26 years of age. The effect of baseline characteristics of subjects on vaccine-induced HPV antibody respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Petersen, Lone K., Restrepo, Jaime, Moreira, Edson D., Iversen, Ole-Erik, Pitisuttithum, Punnee, Van Damme, Pierre, Joura, Elmar A., Olsson, Sven-Erik, Ferris, Daron, Block, Stan, Giuliano, Anna R., Bosch, Xavier, Pils, Sophie, Cuzick, Jack, Garland, Suzanne M., Huh, Warner, Kjaer, Susanne K., Bautista, Oliver M., Hyatt, Donna, Maansson, Roger, Moeller, Erin, Qi, Hong, Roberts, Christine, Luxembourg, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883201/
https://www.ncbi.nlm.nih.gov/pubmed/28720442
http://dx.doi.org/10.1016/j.pvr.2017.03.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883201/
https://www.ncbi.nlm.nih.gov/pubmed/28720442
http://dx.doi.org/10.1016/j.pvr.2017.03.002

Ejemplares similares